LX211 and LX201 for uveitis and corneal transplant rejectio

[Mike Bartolatz]

http://www.medicalnewstoday.com/medical ... wsid=60833

LX211 is in clinical trials for non infectious uveitis. it would be the FIRST drug approved for treatment of uveitis if it succeeds.

LX201 is for corneal transpant rejection and is an implanted device

[Mike Bartolatz]

http://clinicaltrials.gov/show/NCT00404742

phase III trials underway on LX211

trials of LX201 expected end of 1st quarter 2007

[Mike Bartolatz]

http://micro.newswire.ca/release.cgi?rk ... rt=0&htm=0

it could be quiet some time before Luveniq is approved for uveitis. the FDA has requested an additional trial be done for safety of Voclosporine in the treatment of intermediate and posterior uveitis.